Skip to main content
. Author manuscript; available in PMC: 2018 Sep 26.
Published in final edited form as: Pharmacogenomics J. 2015 Jan 20;15(5):422–429. doi: 10.1038/tpj.2014.83

Figure 4.

Figure 4.

Changes of %FEV1 mean (±SE) by the mutant homozygote (MM) over a mix of the homozygote for the wild-type allele and the heterozygote for the two different alleles (W_) at an intermediate dose of glucocorticoids for significant SNPs, chr6 rs6924808 (A), chr8 rs10481450 (B), chr11 rs1353649 (C), chr15 rs12438740 (D), and chr15 rs2230155 (E), for pooled IMPACT, SOCS and SLIC trials detected by the recessive model. Note that %FEV1 was not normalized because these trials contain only one dose of glucocorticoids.